Data compiled by Redley Lamar · ChainSifter Intelligence
11Suppliers
5Customers
2Debt Items
4Related Chains
Source-Backed Evidence Depth
BriaCell Therapeutics Corp. (BCTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
19Total relationships
5Distinct source URLs
18High confidence
0.857Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BriaCell Therapeutics Corp. Suppliers
Ticker
Name
Confidence
Evidence
BC-THERAPEUTICS-INC
BC-THERAPEUTICS-INC
92%
The Company has a 65 % interest in BC Therapeutics.
BC-THERAPEUTICS
BC-THERAPEUTICS
90%
The Company has a 67.8% interest in BC Therapeutics.
INFOWORKS
INFOWORKS
90%
The Company entered into a Service and Technology Agreement (“MSTA”) agreement with InfoWorks to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastati…
THINKEQUITY-LLC
THINKEQUITY-LLC
90%
The Company paid the Placement Agent a cash fee of 7.5% of the aggregate gross proceeds and also issued to the Placement Agent warrants to purchase 72,465 common shares
UC-DAVIS
UC-DAVIS
90%
The Company pays UC Davis certain hourly rates depending on the specific services provided by UC Davis in connection with its manufacturing of Bria-IMT™.
UNIVERSITY-OF-MARYLAND-BALTIMORE-COUNTY
UNIVERSITY-OF-MARYLAND-BALTIMORE-COUNTY
90%
BriaCell Therapeutics Corp. entered into a licensing agreement with University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treat…
FUJIFILM-DIOSYNTH-BIOTECHNOLOGY
FUJIFILM-DIOSYNTH-BIOTECHNOLOGY
85%
Bria-IMT™ is currently manufactured under current Good Manufacturing Practices ("cGMP") pursuant to agreements with UC Davis and with FujiFilm Diosynth Biotechnology ("Fuji"), which is located in Tho…
FALLER-WILLIAMS-TECHNOLOGY
FALLER-WILLIAMS-TECHNOLOGY
80%
BriaCell acquired the license agreement Sapientia entered into with Faller-Williams Technology ("FWT"), dated March 16, 2017 (the "License Agreement")
PREVAIL-PARTNERS
PREVAIL-PARTNERS
80%
In May 2023, Prevail Partners, LLC ("Prevail Partners"), an investment fund and affiliate of InfoWorks invested $4 million in the company at a 20% premium to the trailing thirty (30) trading day volu…
SAPIENTIA
SAPIENTIA
80%
BriaCell acquired the license agreement Sapientia entered into with Faller-Williams Technology ("FWT"), dated March 16, 2017 (the "License Agreement")
UMBC
UMBC
80%
BriaCell originally secured the exclusive license from the University of Maryland, Baltimore County.
BriaCell Therapeutics Corp. Customers
Ticker
Name
Confidence
Evidence
BRIAPRO
BRIAPRO
90%
BriaPro has agreed to purchase BriaCell’s exclusive license to develop and commercialize Soluble CD80.
Reciprocal relationship from HYFT graph: Reciprocal relationship from BCTX graph: Reciprocal relationship from HYFT graph: Reciprocal relationship from BCTX graph: Reciprocal relationship from HYFT g…
MSK
MSK
90%
On October 21, 2025, we further announced a collaboration with MSK's Therapeutics Accelerator program focused on the Bria-OTS+ platform.
PREVAIL-PARTNERS-LLC
PREVAIL-PARTNERS-LLC
80%
In May 2023, Prevail Partners, LLC ("Prevail Partners"), an investment fund and affiliate of InfoWorks, purchased 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million
BC-THERAPEUTICS-INC
BC-THERAPEUTICS-INC
62%
s are classified as equity instruments or liability awards and situations where they fall outside ASC Topic 718, being accounted for under ASC Topic 710. The ASU is effective for years beginning afte…
BriaCell Therapeutics Corp. Debt Obligations
Instrument
Description
Confidence
Evidence
BCTX-DEBT-8106
Warrants outstanding: 5.31
90%
xbrl warrant detail from xbrl 2025-07-31.
BCTX-DEBT-8107
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-07-31.
BriaCell Therapeutics Corp. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BriaCell Therapeutics Corp..
BriaCell Therapeutics Corp. Ownership
Holder
Name
Confidence
Evidence
BCTX-OWNER-CABLE-CAR-CAPITAL-LP
Cable Car Capital, LP
90%
13F overlay lists Cable Car Capital, LP as top holder; 16 tracked holders.
